Skip to the answer

Ixekizumab Injection

Ixekizumab injection (Taltz) is a targeted biologic that treats moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in eligible adults and children.

Brand name Taltz
Drug class Interleukin-17a Antagonist
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 6, 2026
Ixekizumab Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Taltz (ixekizumab) is a specialist biologic injection, on the market since about 2016, that blocks IL-17A (an immune signal that drives inflammation) to treat moderate-to-severe plaque psoriasis from age 6 and, in adults, psoriatic arthritis and inflammatory spinal arthritis such as ankylosing spondylitis, usually once creams or older treatments fall short. Most people tolerate it well, and what they notice most is redness or stinging at the injection site, more colds, and occasionally thrush (a mouth yeast infection). The one thing to watch is infection, because Taltz dampens part of your immune defenses, so expect a tuberculosis test before starting and report fever or a lasting cough.

Clinical pearls

  • Let the autoinjector sit out of the fridge about 30 minutes with the cap on, since a room-temperature dose usually stings less.
  • Get any needed vaccines before starting, because live vaccines, such as the nasal spray flu vaccine, must be avoided while on Taltz.
  • Report new belly pain, diarrhea or bloody stool promptly, since Taltz can trigger or worsen Crohn's disease or ulcerative colitis.
  • Rotate between thigh, belly and upper arm, and flag any new eczema-like rash that appears after starting.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asInjection
Earliest FDA record2016
Companies listing it with the FDA1
FDA label last updatedJan 22, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Ixekizumab Injection, written from its FDA label.

What Ixekizumab Injection is used for

▾

Ixekizumab injection is a targeted biologic approved to treat several immune-driven inflammatory conditions.

  • Taltz treats moderate-to-severe plaque psoriasis in patients 6 years of age and older who are candidates for systemic therapy or phototherapy
  • Taltz treats active psoriatic arthritis in adults — it may be used alone or with a conventional DMARD such as methotrexate; patients who also have moderate-to-severe plaque psoriasis follow the adult psoriasis dosing schedule
  • Taltz treats active ankylosing spondylitis in adults
  • Taltz treats active non-radiographic axial spondyloarthritis (nr-axSpA) — a form of spinal inflammatory arthritis that doesn't show bone damage on X-rays but has measurable signs of inflammation — in adults

How Ixekizumab Injection works

▾

Ixekizumab is a humanized monoclonal antibody — an engineered protein that precisely targets a single immune messenger called interleukin-17A (IL-17A). IL-17A is naturally produced during immune responses, but in conditions like psoriasis and inflammatory arthritis, it's overactive — driving the redness, scaling, and joint inflammation those diseases are known for. By binding tightly to IL-17A and blocking it from activating its receptor, ixekizumab quiets this overactive signal and reduces the release of other pro-inflammatory chemicals (cytokines and chemokines).

Ixekizumab Injection dosage

▾

Taltz is given as a subcutaneous injection (under the skin) and is not taken by mouth. The injection schedule varies by condition — most regimens begin with a higher starting dose, then shift to a maintenance dose given every 4 weeks. For pediatric plaque psoriasis, the dose is also adjusted by the child's weight. For non-radiographic axial spondyloarthritis, Taltz is given once every 4 weeks without an initial higher starting dose.

  • Rotate injection sites each time (thigh, abdomen, or upper arm) and avoid skin that is tender, bruised, or affected by psoriasis
  • Let Taltz warm to room temperature for 30 minutes before injecting; keep the needle cap on during warming
  • If a dose is missed, take it as soon as you remember, then return to your regular schedule
  • Food does not affect subcutaneous injections — there are no food-related timing restrictions

Dosing details from the FDA-approved label

From the Ixekizumab Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adult plaque psoriasis (moderate-to-severe)
    • 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks
    • Administered by subcutaneous injection
  • Pediatric plaque psoriasis, patients weighing greater than 50 kg
    • 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks
    • Pediatric patients 6 to less than 18 years of age; weight-based
  • Pediatric plaque psoriasis, patients weighing 25 to 50 kg
    • 80 mg at Week 0, followed by 40 mg every 4 weeks
    • Pediatric patients 6 to less than 18 years of age; weight-based
  • Pediatric plaque psoriasis, patients weighing less than 25 kg
    • 40 mg at Week 0, followed by 20 mg every 4 weeks
    • Pediatric patients 6 to less than 18 years of age; weight-based
  • Psoriatic arthritis
    • 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks
    • With coexistent moderate-to-severe plaque psoriasis, use the adult plaque psoriasis regimen
  • Ankylosing spondylitis
    • 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks
  • Non-radiographic axial spondyloarthritis
    • 80 mg by subcutaneous injection every 4 weeks
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Administer by subcutaneous injection. Adult Plaque Psoriasis ( 2.2 ) Recommended dosage is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks. Pediatric Plaque Psoriasis ( 2.3 ) For patients weighing greater than 50 kg, recommended dosage is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. For patients weighing 25-50 kg, recommended dosage is 80 mg at Week 0, followed by 40 mg every 4 weeks. For patients weighing less than 25 kg, recommended dosage is 40 mg at Week 0, followed by 20 mg every 4 weeks. Psoriatic Arthritis ( 2.4 ) Recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis. ( 2.2 ) TALTZ may be administered alone or in combination with a conventional DMARD (e.g., methotrexate). Ankylosing Spondylitis ( 2.5 ) Recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. Non-radiographic Axial Spondyloarthritis ( 2.6 ) Recommended dosage is 80 mg by subcutaneous injection every 4 weeks. 2.1 Testing and Procedures Prior to Treatment Initiation Perform the following evaluations prior to TALTZ initiation: Evaluate patients for tuberculosis (TB) infection. TALTZ initiation is not recommended in patients with active TB infection. Initiate treatment of latent TB prior to initiation of TALTZ [see Warnings and Precautions ( 5.2 )] . Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with TALTZ [see Warnings and Precautions ( 5.6 )] . 2.2 Recommended Dosage in Adult Plaque Psoriasis TALTZ is administered by subcutaneous injection. The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks. 2.3 Recommended Dosage in Pediatric Plaque Psoriasis TALTZ is administered by subcutaneous injection every 4 weeks (Q4W). The recommended dosage in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis is based on the following weight categories.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Ixekizumab Injection side effects

▾

The most common side effects with Taltz include:

Common side effects

  • Injection site reactions (redness, pain, or swelling at the injection site)
  • Upper respiratory tract infections (such as a common cold or runny nose)
  • Nausea
  • Tinea infections (fungal skin infections)
  • Oral candidiasis (thrush — a yeast infection in the mouth)
  • Conjunctivitis (pink eye)
  • Injection site reactions — redness, pain, or swelling where you inject

When to get medical help

  • Signs of serious infection (high fever, chills, persistent cough, wounds that won't heal) — contact your doctor right away
  • Signs of tuberculosis (TB), such as a lasting cough, night sweats, or unexplained weight loss
  • Signs of a severe allergic reaction — hives, difficulty breathing, swelling of the face, lips, tongue, or throat — seek emergency help immediately
  • New or worsening skin rashes, including eczema-like eruptions — tell your doctor if your skin develops new or unusual changes
  • Symptoms of inflammatory bowel disease — stomach pain, diarrhea, or blood in your stool — contact your doctor promptly

More serious reactions — including severe allergic responses (anaphylaxis), serious infections, severe eczema-like skin eruptions, and new or worsening inflammatory bowel disease — require prompt medical attention and may mean stopping Taltz.

Ixekizumab Injection warnings and precautions

▾
  • Serious infections: Taltz lowers immune defenses. Serious bacterial, viral, and fungal infections have been reported. Tell your doctor right away if you develop a fever, chills, persistent cough, or any sign of infection that isn't getting better.
  • Tuberculosis (TB): You must be screened for TB before starting Taltz. Active TB is a contraindication; latent (dormant) TB must be treated first. Stay alert for TB symptoms — lasting cough, night sweats, weight loss — throughout treatment.
  • Serious allergic reactions: Anaphylaxis and other severe hypersensitivity reactions have occurred. Seek emergency care immediately if you have trouble breathing, throat swelling, or a sudden severe rash.
  • Eczematous eruptions: Some people develop severe eczema-like skin reactions after starting Taltz — sometimes needing hospitalization. These can appear days to months after the first dose. Tell your doctor about any new or worsening skin changes.
  • Inflammatory bowel disease: Crohn's disease and ulcerative colitis have occurred or worsened in people taking Taltz. Report ongoing stomach pain, diarrhea, or blood in your stool.
  • Live vaccines: Avoid live vaccines while on Taltz. Complete recommended vaccinations before starting treatment.

Ixekizumab Injection interactions

▾

The FDA label for Taltz does not detail specific drug-drug interactions, but there are important precautions related to other treatments:

  • Live vaccines — must be avoided while taking Taltz, as the reduced immune response could make live vaccines unsafe or ineffective; complete all age-appropriate vaccines before starting
  • Conventional DMARDs (e.g., methotrexate) — Taltz may be used alongside these for psoriatic arthritis, as directed by your prescriber

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿53 supplements and herbs with documented Ixekizumab Injection interactions, ranked by severity Check Ixekizumab Injection against a supplement or herb →

Before taking Ixekizumab Injection

▾
  • Active serious hypersensitivity to ixekizumab or any ingredient in Taltz — this is a contraindication; do not use Taltz if you've had a severe allergic reaction to it before
  • Active or latent TB — must be evaluated and, if needed, treated before starting Taltz
  • Ongoing or recurring infections — tell your doctor about any current infections or a history of frequent infections
  • Inflammatory bowel disease — Crohn's disease or ulcerative colitis may worsen; discuss with your doctor
  • Pregnancy — data are insufficient to confirm safety; the drug may cross the placenta. A pregnancy registry (1-800-284-1695) is available for women who use Taltz while pregnant
  • Breastfeeding — it is unknown whether ixekizumab passes into human milk; discuss benefits and risks with your doctor
  • Children under 6 — safety and effectiveness have not been established in this age group
  • Adults 65 and older — no meaningful differences in safety or effectiveness have been observed, but limited data are available

How your body processes Ixekizumab Injection

▾

After a subcutaneous injection, ixekizumab is absorbed gradually — peak blood levels are reached in about 4 days. Injecting into the thigh achieves slightly higher absorption compared to the arm or abdomen. Bioavailability (the amount that actually reaches the bloodstream) ranges from about 60% to 81%.

The drug has a half-life of about 13 days, meaning it takes roughly two weeks for half of a dose to clear from the body. It is broken down through the body's normal protein recycling pathways — not processed by the liver enzymes that handle most oral medications. Body weight affects how quickly ixekizumab is cleared, with higher body weight leading to faster clearance. Age does not significantly affect how the drug is processed in adults.

How to store Ixekizumab Injection

▾

Store refrigerated at 2°C to 8°C (36°F to 46°F). store TALTZ at room temperature up to 30°C (86°F) for up to 5 days in the original carton to protect from light. stored at room temperature, do not return to the refrigerator and discard, if unused, within 5 days.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

53

Supplements & herbs that interact with Ixekizumab Injection

53 supplements and herbal products have documented interactions with Ixekizumab Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Moderate · 52
  • Minor · 1
ACTIVE HEXOSE CORRELATED COMPOUND (AHCC) Moderate ALFALFA Moderate AMERICAN GINSENG Moderate ANDROGRAPHIS Moderate ASHWAGANDHA Moderate ASTRAGALUS Moderate BEE VENOM Moderate BETA-GLUCANS Moderate +45 more
Every supplement checked against Ixekizumab Injection — ranked by severity The full interaction hub: 52 moderate · 1 minor · every one linked to its full report. Check Ixekizumab Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Ixekizumab Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Ixekizumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is Taltz used for?

▾
Taltz is approved to treat moderate-to-severe plaque psoriasis in people 6 years and older, and for adults it also treats psoriatic arthritis, ankylosing spondylitis, and a condition called non-radiographic axial spondyloarthritis — which is spinal inflammatory arthritis that shows active inflammation but not yet visible bone damage on X-rays. Your doctor prescribed it because it targets the specific immune pathway driving your condition.

How do I give myself the injection, and does it hurt?

▾
Take Taltz out of the fridge 30 minutes before your injection and let it warm up with the needle cap still on — injecting a cold solution can sting more. Choose a spot on your thigh, abdomen, or upper arm, rotating to a different site each time, and avoid skin that is sore, bruised, or affected by psoriasis. Some injection site redness or discomfort is common and usually mild. Your healthcare team will walk you through the technique before you try it on your own.

I feel like I'm coming down with a cold — should I skip my Taltz dose?

▾
Don't just skip a dose without calling your doctor or pharmacist first. Taltz does lower your immune defenses, so your doctor will want to know about any infection — even what feels like a mild cold — especially if it isn't improving. For a serious infection like high fever, chills, or symptoms that aren't getting better, your doctor may advise pausing Taltz until you recover.

Are there any vaccines I need to worry about?

▾
Yes — live vaccines (like live shingles vaccine or live flu spray) should be avoided while you're on Taltz. Because Taltz affects your immune system, a live vaccine could potentially cause an infection. Before you start Taltz, your doctor should make sure all your recommended vaccines are up to date. Inactivated vaccines (like the standard flu shot) can generally still be given, but always check with your doctor first.

Is it safe to use Taltz if I'm pregnant or breastfeeding?

▾
There isn't enough human data yet to say for certain whether Taltz is safe during pregnancy. The drug can cross the placenta, so there could be effects on the baby. If you become pregnant while taking Taltz, there's a registry you can join — call 1-800-284-1695 — that tracks outcomes to help answer these questions. For breastfeeding, it's unknown whether ixekizumab passes into breast milk, so talk with your doctor about the best approach for you and your baby.

What side effects should I actually call my doctor about versus just wait out?

▾
Mild injection site reactions, a stuffy nose, or brief nausea are common and usually not dangerous — you can mention them at your next visit. But call your doctor right away if you develop signs of a serious infection (high fever, persistent cough, wounds not healing), symptoms of a severe allergic reaction (trouble breathing, swelling of the face or throat), new or worsening stomach pain with diarrhea or blood in your stool, or any unusual skin rash or eczema-like eruption that's spreading or getting worse.

Is Ixekizumab Injection available over the counter?

▾
No. Ixekizumab Injection is a prescription medicine: every Ixekizumab Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Ixekizumab Injection first available?

▾
The earliest FDA record we hold for Ixekizumab Injection is from 2016: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Ixekizumab Injection was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Ixekizumab Injection on HelloPharmacist

📊Ixekizumab Injection supplement interactions53 checked — ranked by severity 🌿Drug & Supplement CheckerIxekizumab Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Ixekizumab Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Ixekizumab Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Ixekizumab Injection forms and strengths (how it comes)

Ixekizumab Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Ixekizumab Injection inactive ingredients by manufacturer.

Injection

By injection · Under the skin
Brands Taltz
How this form is used
What it may be used for
  • Taltz is used to treat moderate-to-severe plaque psoriasis in patients 6 years of age and older
  • Taltz treats active psoriatic arthritis in adults, alone or combined with a cDMARD such as methotrexate
  • Taltz treats active ankylosing spondylitis in adults
  • Taltz treats active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
Important instructions
  • Taltz is given as a subcutaneous (under-the-skin) injection in the thigh, abdomen, or upper arm — rotate sites with each dose
  • Remove Taltz from the refrigerator 30 minutes before injecting and let it reach room temperature with the needle cap still on
  • Inspect Taltz before use — it should be clear and colorless to slightly yellow; do not use if cloudy, discolored, or if particles are visible
  • Taltz contains no preservatives — discard any unused portion after use; if a dose is missed, inject as soon as possible then resume the regular schedule
Available strengths 3 strengths
20 mg/0.25 mL 40 mg/0.5 mL 80 mg/mL
11 FDA-listed product records ⓘ

Ixekizumab Injection on the U.S. market: products, makers and brands

How Ixekizumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 4 Ixekizumab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2016. Brand names on the directory include Taltz; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
4
FDA-listed product records ⓘ
2016
Earliest FDA record ⓘ

How widely Ixekizumab Injection is used (Medicaid data)

A general measure of how commonly Ixekizumab Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Ixekizumab Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

72,831
Medicaid prescriptions filled (Q1–Q4 2025)
$584.3M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Ixekizumab Injection prescribed? Of the 1,601 medications we measure, Ixekizumab Injection ranks #556 by Medicaid prescriptions — more than 65% of them.

Where Ixekizumab Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #556 of 1,601
#551 Rifampin 77,313 Rx #552 Clindamycin Vaginal 76,615 Rx #553 Ruxolitinib Topical 76,226 Rx #554 Calcipotriene Topical 74,990 Rx #555 Clotrimazole Vaginal 73,195 Rx #556 Ixekizumab Injection 72,831 Rx #557 Pentoxifylline 72,461 Rx #558 Magnesium Hydroxide 72,007 Rx #559 Denosumab Injection 71,350 Rx #560 Cromolyn Ophthalmic 71,026 Rx #561 Cabergoline 70,969 Rx

Utilization by Ixekizumab Injection product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 1 mL / 80 mg/mL auto-injector is the most-dispensed Ixekizumab Injection product — about 95% of these Medicaid prescriptions.

1 ML ixekizumab 80 MG/ML Auto-Injector Most dispensed

69,283 Medicaid prescriptions (Q1–Q4 2025) 95% of Ixekizumab Injection prescriptions shown $556.6M gross reimbursement (before rebates) ≈ $8,034 per prescription (gross)

Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1745103

1 ML ixekizumab 80 MG/ML Prefilled Syringe

2,903 Medicaid prescriptions (Q1–Q4 2025) 4% of Ixekizumab Injection prescriptions shown $23.2M gross reimbursement (before rebates) ≈ $7,986 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1745112

0.5 ML ixekizumab 80 MG/ML Prefilled Syringe

633 Medicaid prescriptions (Q1–Q4 2025) <1% of Ixekizumab Injection prescriptions shown $4.5M gross reimbursement (before rebates) ≈ $7,107 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2674933

0.25 ML ixekizumab 80 MG/ML Prefilled Syringe

12 Medicaid prescriptions (Q1–Q4 2025) <1% of Ixekizumab Injection prescriptions shown $48,128 gross reimbursement (before rebates) ≈ $4,011 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2674931

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Ixekizumab Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 6 of 12 listed Ixekizumab Injection NDCs with Medicaid activity.

Compare Ixekizumab Injection products

A representative set of FDA-listed product records for Ixekizumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
20 mg/0.25 mL Subcutaneous Eli Lilly and Company BLA View NDC →
40 mg/0.5 mL Subcutaneous Eli Lilly and Company BLA View NDC →
80 mg/mL Subcutaneous Eli Lilly and Company × 2 listings BLA View NDC →

Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Ixekizumab Injection NDCs →

Ixekizumab Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Ixekizumab recalls since July 2021.

✅No Ixekizumab recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Ixekizumab Injection RxCUI 1745099 2 dose forms · 4 strengths
  1. Dose form (SCDF) Auto-Injector RxCUI 1745102 In current FDA listings
    Clinical drug / strength (SCD) 1 ML ixekizumab 80 MG/ML RxCUI 1745103

Look up RxCUI 1745099 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Ixekizumab Injection costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Injection, Solution · Subcutaneous 80 mg/mL $7,370.72–$7,435.87 per mL NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Ixekizumab Injection brand names

Ixekizumab Injection is sold under one brand name in the FDA directory — Taltz. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Taltz

Who makes Ixekizumab Injection: manufacturers and labelers

One company lists Ixekizumab Injection products with the FDA. By number of product records, the largest are Eli Lilly and Company. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Eli Lilly and Company 4

Ixekizumab Injection drug class (RxNorm)

Ixekizumab Injection belongs to the Interleukin-17A Antagonist class.

Pharmacologic class Interleukin-17A Antagonist
Drug family (ATC) Interleukin inhibitors
How it works Interleukin-17A Antagonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Ixekizumab Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jan 22, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Ixekizumab Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Ixekizumab Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
4
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Eli Lilly and Company
Linked label effective
Jan 22, 2026
Composite sections available
22
Linked SPL Set ID
ac96658a-d7dc-4c7c-8928-2adcdf4318b2
Linked SPL Document ID
1c6425de-1f8c-4385-bfb9-6e01db55275f
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Eli Lilly and Company is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →